These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 34669604)

  • 1. Immunogenicity and potential protection of DNA vaccine of Leishmania martiniquensis against Leishmania infection in mice.
    Aunguldee T; Gerdprasert O; Tangteerawatana P; Jariyapongskul A; Leelayoova S; Wongsatayanon BT
    J Infect Dev Ctries; 2021 Sep; 15(9):1328-1338. PubMed ID: 34669604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis.
    Aguilar-Be I; da Silva Zardo R; Paraguai de Souza E; Borja-Cabrera GP; Rosado-Vallado M; Mut-Martin M; García-Miss Mdel R; Palatnik de Sousa CB; Dumonteil E
    Infect Immun; 2005 Feb; 73(2):812-9. PubMed ID: 15664920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
    Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
    Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis.
    Saljoughian N; Taheri T; Zahedifard F; Taslimi Y; Doustdari F; Bolhassani A; Doroud D; Azizi H; Heidari K; Vasei M; Namvar Asl N; Papadopoulou B; Rafati S
    PLoS Negl Trop Dis; 2013; 7(4):e2174. PubMed ID: 23638195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice.
    Saljoughian N; Zahedifard F; Doroud D; Doustdari F; Vasei M; Papadopoulou B; Rafati S
    Parasite Immunol; 2013 Dec; 35(12):397-408. PubMed ID: 23710803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral leishmaniasis.
    Ramirez L; Corvo L; Duarte MC; Chávez-Fumagalli MA; Valadares DG; Santos DM; de Oliveira CI; Escutia MR; Alonso C; Bonay P; Tavares CA; Coelho EA; Soto M
    Parasit Vectors; 2014 Jan; 7():3. PubMed ID: 24382098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.
    Bhowmick S; Ravindran R; Ali N
    Infect Immun; 2008 Mar; 76(3):1003-15. PubMed ID: 18195029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Leishmanization Using
    Keshavarzian N; Noroozbeygi M; Haji Molla Hoseini M; Yeganeh F
    Front Immunol; 2020; 11():1725. PubMed ID: 33193290
    [No Abstract]   [Full Text] [Related]  

  • 9. A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis.
    Oliveira-da-Silva JA; Machado AS; Ramos FF; Tavares GSV; Lage DP; Mendonça DVC; Pereira IAG; Santos TTO; Martins VT; Carvalho LM; Freitas CS; Ludolf F; Reis TAR; Bandeira RS; Silva AM; Costa LE; Oliveira JS; Duarte MC; Roatt BM; Teixeira AL; Coelho EAF
    Cell Immunol; 2020 Oct; 356():104194. PubMed ID: 32827943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis.
    Walker PS; Scharton-Kersten T; Rowton ED; Hengge U; Bouloc A; Udey MC; Vogel JC
    Hum Gene Ther; 1998 Sep; 9(13):1899-907. PubMed ID: 9741428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals.
    Khoshgoo N; Zahedifard F; Azizi H; Taslimi Y; Alonso MJ; Rafati S
    Vaccine; 2008 Oct; 26(46):5822-9. PubMed ID: 18804512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA-protein immunization using Leishmania peroxidoxin-1 induces a strong CD4+ T cell response and partially protects mice from cutaneous leishmaniasis: role of fusion murine granulocyte-macrophage colony-stimulating factor DNA adjuvant.
    Bayih AG; Daifalla NS; Gedamu L
    PLoS Negl Trop Dis; 2014 Dec; 8(12):e3391. PubMed ID: 25500571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC; Yang J; Zhao W; Perez LE; Cheng J
    Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Total Leishmania antigens with Poly(I:C) induce Th1 protective response.
    Sanchez MV; Eliçabe RJ; Di Genaro MS; Germanó MJ; Gea S; García Bustos MF; Salomón MC; Scodeller EA; Cargnelutti DE
    Parasite Immunol; 2017 Nov; 39(11):. PubMed ID: 28901553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leishmania major p27 gene knockout as a novel live attenuated vaccine candidate: Protective immunity and efficacy evaluation against cutaneous and visceral leishmaniasis in BALB/c mice.
    Elikaee S; Mohebali M; Rezaei S; Eslami H; Khamesipour A; Keshavarz H; Eshraghian MR
    Vaccine; 2019 May; 37(24):3221-3228. PubMed ID: 31047672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leishmania donovani serine protease encapsulated in liposome elicits protective immunity in experimental visceral leishmaniasis.
    Das P; Paik D; Naskar K; Chakraborti T
    Microbes Infect; 2018 Jan; 20(1):37-47. PubMed ID: 28970116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA immunization with the gene encoding P4 nuclease of Leishmania amazonensis protects mice against cutaneous Leishmaniasis.
    Campbell K; Diao H; Ji J; Soong L
    Infect Immun; 2003 Nov; 71(11):6270-8. PubMed ID: 14573646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice.
    Campos-Neto A; Webb JR; Greeson K; Coler RN; Skeiky YA; Reed SG
    Infect Immun; 2002 Jun; 70(6):2828-36. PubMed ID: 12010969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections.
    Zanin FH; Coelho EA; Tavares CA; Marques-da-Silva EA; Silva Costa MM; Rezende SA; Gazzinelli RT; Fernandes AP
    Microbes Infect; 2007 Jul; 9(9):1070-7. PubMed ID: 17644455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C-terminal domain deletion enhances the protective activity of cpa/cpb loaded solid lipid nanoparticles against Leishmania major in BALB/c mice.
    Doroud D; Zahedifard F; Vatanara A; Taslimi Y; Vahabpour R; Torkashvand F; Vaziri B; Rouholamini Najafabadi A; Rafati S
    PLoS Negl Trop Dis; 2011 Jul; 5(7):e1236. PubMed ID: 21765963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.